Form 8-K - Current report:
SEC Accession No. 0001104659-22-067880
Filing Date
2022-06-03
Accepted
2022-06-03 08:54:00
Documents
12
Period of Report
2022-06-02
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2217603d1_8k.htm   iXBRL 8-K 33829
  Complete submission text file 0001104659-22-067880.txt   209111

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA anvs-20220602.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20220602_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20220602_pre.xml EX-101.PRE 22599
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2217603d1_8k_htm.xml XML 3707
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 22993002
SIC: 2834 Pharmaceutical Preparations